← Eichor
Study identifier: NCT05968898 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Assessment of a Radiomics-based Computer-Aided Diagnosis Tool for Pulmonary nodulES

Condition: Lung Cancer · Pulmonary Nodule, Solitary  ·  Sponsor: Abramson Cancer Center at Penn Medicine

PhaseNA
Planned participants300
Who can joinAll sexes, 35 Years to 89 Years
Healthy volunteersNo

About this study

This is a pragmatic clinical trial that will study the effect of a radiomics-based computer-aided diagnosis (CAD) tool on clinicians' management of pulmonary nodules (PNs) compared to usual care. Adults aged 35-89 years with 8-30mm PNs evaluated at Penn Medicine PN clinics will undergo 1:1 randomization to one of two groups, defined by the PN malignancy risk stratification strategy used by evaluating clinicians: 1) usual care or 2) usual care + use of a radiomics-based CAD tool.

This description comes directly from the study's public registry record.

Talk to the study team

Roger Y. Kim, MD, MSCE  ·  215-662-3677  ·  roger.kim@pennmedicine.upenn.edu

Anil Vachani, MD, MSCE  ·  215-573-7931  ·  avachani@pennmedicine.upenn.edu

Always discuss trial participation with your own doctor first.

Locations (3)

Penn Medicine University CityPhiladelphia, Pennsylvania, United StatesRecruiting
Perelman Center for Advanced MedicinePhiladelphia, Pennsylvania, United StatesRecruiting
Penn Medicine Washington SquarePhiladelphia, Pennsylvania, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05968898